To investigate treatment factors predicting favorable clinical response to EP102 (oral fospropofol), a propofol prodrug under development for acute treatment of migraine.
No takes yet. Share an insight, caveat, or question.
Heller et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: